Literature DB >> 21922510

Impact of TET2 mutations on mRNA expression and clinical outcomes in MDS patients treated with DNA methyltransferase inhibitors.

Daniel A Pollyea, Aparna Raval, Brenda Kusler, Jason R Gotlib, Ash A Alizadeh, Beverly S Mitchell.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 21922510     DOI： 10.1002/hon.976

Source DB:  PubMed          Journal:  Hematol Oncol        ISSN： 0278-0232            Impact factor:   5.271


× No keyword cloud information.
  13 in total

1.  The Impact of DNA Methylation in Hematopoietic Malignancies.

Authors:  Maria Guillamot; Luisa Cimmino; Iannis Aifantis
Journal:  Trends Cancer       Date:  2016-02-01

2.  The HARE-HTH and associated domains: novel modules in the coordination of epigenetic DNA and protein modifications.

Authors:  L Aravind; Lakshminarayan M Iyer
Journal:  Cell Cycle       Date:  2012-01-01       Impact factor: 4.534

Review 3.  Mutations in epigenetic regulators in myelodysplastic syndromes.

Authors:  Gorica Nikoloski; Bert A van der Reijden; Joop H Jansen
Journal:  Int J Hematol       Date:  2012-01-11       Impact factor: 2.490

4.  Baseline and serial molecular profiling predicts outcomes with hypomethylating agents in myelodysplastic syndromes.

Authors:  Anthony M Hunter; Rami S Komrokji; Seongseok Yun; Najla Al Ali; Onyee Chan; Jinming Song; Mohammad Hussaini; Chetasi Talati; Kendra L Sweet; Jeffrey E Lancet; Eric Padron; Alan F List; David A Sallman
Journal:  Blood Adv       Date:  2021-02-23

5.  Down-regulation of TET2 in CD3⁺ and CD34⁺ cells of myelodysplastic syndromes and enhances CD34⁺ cells proliferation.

Authors:  Wei Zhang; Zonghong Shao; Rong Fu; Huaquan Wang; Lijuan Li; Hui Liu
Journal:  Int J Clin Exp Pathol       Date:  2015-09-01

Review 6.  Mutations in epigenetic modifiers in the pathogenesis and therapy of acute myeloid leukemia.

Authors:  Omar Abdel-Wahab; Ross L Levine
Journal:  Blood       Date:  2013-05-02       Impact factor: 22.113

Review 7.  The Ten-Eleven Translocation-2 (TET2) gene in hematopoiesis and hematopoietic diseases.

Authors:  E Solary; O A Bernard; A Tefferi; F Fuks; W Vainchenker
Journal:  Leukemia       Date:  2013-11-13       Impact factor: 11.528

Review 8.  Myeloid malignancies: mutations, models and management.

Authors:  Anne Murati; Mandy Brecqueville; Raynier Devillier; Marie-Joelle Mozziconacci; Véronique Gelsi-Boyer; Daniel Birnbaum
Journal:  BMC Cancer       Date:  2012-07-23       Impact factor: 4.430

9.  TET2 Expression in Bone Marrow Mononuclear Cells of Patients with Myelodysplastic Syndromes and Its Clinical Significances.

Authors:  Wei Zhang; Zong-Hong Shao; Rong Fu; Hua-Quan Wang; Li-Juan Li; Jun Wang; Wen Qu; Yong Liang; Guo-Jin Wang; Xiao-Ming Wang; Yuhong Wu; Hong Liu; Jia Song; Jing Guan; Li-Min Xing
Journal:  Cancer Biol Med       Date:  2012-03       Impact factor: 4.248

10.  TET2 mutations in Ph-negative myeloproliferative neoplasms: identification of three novel mutations and relationship with clinical and laboratory findings.

Authors:  Andrea Patriarca; Donatella Colaizzo; Gianluca Tiscia; Raffaele Spadano; Silvia Di Zacomo; Antonio Spadano; Ida Villanova; Maurizio Margaglione; Elvira Grandone; Alfredo Dragani
Journal:  Biomed Res Int       Date:  2013-05-25       Impact factor: 3.411
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.